Numerous biological events need to be orchestrated at an epigenetic level upon defining cellular fate. Among the key epigenetic regulators are protein methyltransferases (PMTs), which methylate specific Arg/Lys residues with S-adenosyl-L- methionine (SAM) as a cofactor. Whereas many recombinant PMTs are active in vitro, their cellular activities can largely depend on the presence of distinct PMT isoforms or complexes. Such context- dependent complexity makes it challenging to solely rely on conventional methods to elucidate the targets of PMTs. The flexible substrate-recognizing patterns of PMTs, together with their highly- conserved SAM-binding motifs, also made it challenging to develop PMT inhibitors with potency and selectivity. A long-term goal of the project is to elucidate and manipulate methyltransferase- involved epigenetic for disease diagnosis and treatments. The objective of this application is to use SAM mimics as probes to profile cell-type-specific substrates of PMTs and to perturb PMTs in a specific manner. Here an integrative Bioorthogonal Profiling of Protein Methylation (BPPM) will be implemented to dissect the substrates of designated PMTs in relevant biological contexts. A subtype of methylation events associated with specific biological processes will be further validated with well-established methods. Their functional roles will be examined in the context of cancer malignancy or stem cell reprogramming. In parallel, stable SAM analogues will be pursued as target-specific inhibitors against PMTs. The completion of this proposal will unambiguously reveal the substrates of multiple PMTs and characterize high-quality PMT inhibitors in relevant cellular contexts. The impact of these substrate-profiling and inhibitor-identifying strategies further lie n their general applicability to other methyltransferases.

Public Health Relevance

This proposal is expected to uncover the targets of biologically relevant methyltransferases and expand the current collection of methyltransferase inhibitors. The methylation events associated with disease malignancy will be validated and the corresponding inhibitors will be characterized. This work is expected to elicit disease-associated biology and lead to potential therapeutic reagents.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM096056-08
Application #
9483304
Study Section
Synthetic and Biological Chemistry A Study Section (SBCA)
Program Officer
Fabian, Miles
Project Start
2011-02-01
Project End
2019-05-31
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
8
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Luo, Minkui (2018) Chemical and Biochemical Perspectives of Protein Lysine Methylation. Chem Rev 118:6656-6705
Quintero, Cynthia M; Laursen, Kristian B; Mongan, Nigel P et al. (2018) CARM1 (PRMT4) Acts as a Transcriptional Coactivator during Retinoic Acid-Induced Embryonic Stem Cell Differentiation. J Mol Biol 430:4168-4182
Shu, Xiao; Dai, Qing; Wu, Tong et al. (2017) N6-Allyladenosine: A New Small Molecule for RNA Labeling Identified by Mutation Assay. J Am Chem Soc 139:17213-17216
Luo, Minkui (2017) Inhibition of the Kinase Cascade Can Be Quantitative. Biochemistry 56:4443-4444
Aldawsari, Fahad S; Aguayo-Ortiz, Rodrigo; Kapilashrami, Kanishk et al. (2016) Resveratrol-salicylate derivatives as selective DNMT3 inhibitors and anticancer agents. J Enzyme Inhib Med Chem 31:695-703
Warrier, Thulasi; Kapilashrami, Kanishk; Argyrou, Argyrides et al. (2016) N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 113:E4523-30
Tang, Haiping; Li, Jin; Liu, Xiaohui et al. (2016) Down-regulation of HSP60 Suppresses the Proliferation of Glioblastoma Cells via the ROS/AMPK/mTOR Pathway. Sci Rep 6:28388
Butler, Kyle V; Ma, Anqi; Yu, Wenyu et al. (2016) Structure-Based Design of a Covalent Inhibitor of the SET Domain-Containing Protein 8 (SETD8) Lysine Methyltransferase. J Med Chem 59:9881-9889
LaFave, Lindsay M; Béguelin, Wendy; Koche, Richard et al. (2016) Reply to ""Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status"". Nat Med 22:578-9
Wu, Hong; Zheng, Weihong; Eram, Mohammad S et al. (2016) Structural basis of arginine asymmetrical dimethylation by PRMT6. Biochem J 473:3049-63

Showing the most recent 10 out of 34 publications